Joseph Handler, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 774 Christiana Rd Ste 201, Newark, DE 19713 Phone: 610-869-0010 Fax: 610-869-7710 |
Dr. Michael M Moussouttas, MD Psychiatry & Neurology - Vascular Neurology Medicare: Medicare Enrolled Practice Location: 4755 Ogletown Stanton Rd Ste 2e99, Newark, DE 19718 Phone: 302-733-5982 |
Etsegenet F. Tizazu, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Hygeia Dr Ste 1420, Newark, DE 19713 Phone: 302-623-3017 Fax: 302-266-9960 |
John Robert Pollard, MD Medicare: Accepting Medicare Assignments Practice Location: 200 Hygeia Dr Ste 1420, Newark, DE 19713 Phone: 302-623-3017 |
John Townsend Iii, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 774 Christiana Rd, Suite 201, Newark, DE 19713 Phone: 302-731-3017 |
News Archive
A new world-class orthopaedic gait analysis laboratory - the ‘GRAIL' (gait real-time analysis interactive laboratory) - and state-of-the-art virtual reality training equipment have been installed at Bournemouth University's Orthopaedic Research Institute thanks to a £700,000 local growth fund investment secured by Dorset Local Enterprise Partnership.
The drive toward containing health care costs could have the unintended consequence of reducing physician productivity, impairing quality and perhaps even increasing costs, two Beth Israel Deaconess Medical Center physicians suggest in a New England Journal of Medicine "Perspective."
Ghrelin is a hormone released by the stomach and it stimulates appetite and food intake. Alcohol is commonly viewed as a psychoactive substance that primarily affects brain function, but it is also a highly caloric food.
Stem cell scientists have moved one step closer to producing blood-forming stem cells in a Petri dish by identifying a key regulator controlling their formation in the early embryo, shows research published online today in Cell.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
› Verified 1 days ago